Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. September 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018

WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
10. September 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018

WATERTOWN, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic...
31. August 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)

WATERTOWN, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
08. August 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update

Expanded three-month Phase 2 data presented at EULAR 2018 continue to indicate that SEL-212 product profile may provide better and more sustained serum uric acid control, fewer flares and less...
02. August 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018

WATERTOWN, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
01. August 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call

WATERTOWN, Mass., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
15. Juni 2018 05:30 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

3-month Phase 2 data continue to show SEL-212 (SVP-Rapamycin + pegsiticase) may present a superior product profile over current FDA-approved chronic severe gout therapy with serum uric acid (SUA)...
08. Juni 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018

WATERTOWN, Mass., June 08, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
30. Mai 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 06, 2018

WATERTOWN, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies...
09. Mai 2018 08:00 ET | Quelle: Selecta Biosciences, Inc.

Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update

3-month Phase 2 data presented at PANLAR 2018 indicate SEL-212 (SVP-Rapamycin + pegsiticase) product profile may provide better and more sustained serum uric acid control, fewer flares, and less...

Vorherige Seite